B
Bethany Hanusch
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 3
Citations - 301
Bethany Hanusch is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Trk receptor & Targeted therapy. The author has an hindex of 3, co-authored 3 publications receiving 219 citations.
Papers
More filters
Journal ArticleDOI
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
Alexander Drilon,Alexander Drilon,Ramamoorthy Nagasubramanian,James F. Blake,Nora Ku,Brian B. Tuch,Kevin Ebata,Steve Smith,Veronique Lauriault,Kolakowski Gabrielle R,Barbara J. Brandhuber,Paul D. Larsen,Karyn Bouhana,Shannon L. Winski,R. Hamor,Wen-I Wu,Andrew Parker,Tony Morales,Francis X. Sullivan,Walter E. DeWolf,Lance Wollenberg,Paul Gordon,Dorothea N. Douglas-Lindsay,Maurizio Scaltriti,Ryma Benayed,Sandeep Raj,Bethany Hanusch,Alison M. Schram,Philip Jonsson,Michael F. Berger,Michael F. Berger,Jaclyn F. Hechtman,Jaclyn F. Hechtman,Barry S. Taylor,Steve Andrews,S. Michael Rothenberg,David M. Hyman,David M. Hyman +37 more
TL;DR: LOXO-195 abrogated resistance in TRK fusion-positive cancers that acquired kinase domain mutations, a shared liability with all existing TRK TKIs, establishes a role for sequential treatment by demonstrating continued TRK dependence and validates a paradigm for the accelerated development of next-generation inhibitors against validated oncogenic targets.
Proceedings ArticleDOI
Abstract LB-302: Potential role of larotrectinib (LOXO-101), a selective pan-TRK inhibitor, in NTRK fusion-positive recurrent glioblastoma
Alison M. Schram,Barry S. Taylor,Jaclyn F. Hechtman,Ryma Benayed,Lu Wang,Bethany Hanusch,Robert J. Young,Christian Grommes,Nora Ku,David M. Hyman,Thomas Kaley,Alexander Drilon +11 more
TL;DR: The observed mixed response persisting even at the time of drug discontinuation suggests that while heterogeneous, the EML4-NTRK3-mutant subclone was sensitive and responded to larotrectinib therapy, highlighting larot rectinib’s potential role in TRK fusion CNS disease.
Journal ArticleDOI
Genomic Heterogeneity Underlies Mixed Response to Tropomyosin Receptor Kinase Inhibition in Recurrent Glioma
Alison M. Schram,Philip Jonsson,Alexander Drilon,Alexander Drilon,Tejus Bale,Jaclyn F. Hechtman,Ryma Benayed,Bethany Hanusch,Robert J. Young,Christian Grommes,Nora Ku,Thomas Kaley,David M. Hyman,David M. Hyman,Barry S. Taylor +14 more
TL;DR: The case of a young woman with recurrent glioblastoma treated with larotrectinib, a first-in-class, potent and highly selective TRK inhibitor, is reported, to be the first report of the use of aTRK inhibitor in a patient with a TRK fusion-positive gliOBlastoma.